ZyGEM Signs OEM Deal with Quanta Biosciences
News Jul 02, 2012
ZyGEM Corp. Ltd. has announced that it has entered into an agreement with Quanta BioSciences to incorporate ZyGEM’s advanced enzymatic RNA extraction technology into Quanta’s leading reagents for quantitative PCR sold to customers worldwide.
The collaboration will enable Quanta to incorporate ZyGEM’s proprietary technology for the extraction of RNA from diverse samples into its best-in-class reagents for quantitative PCR, which are used to enable sophisticated applications for gene expression, pathogen detection and genetic analyses in diverse industries including pharmaceutical R&D, diagnostics, agribusiness and bio-defense.
“ZyGEM’s RNA extraction technology represents a significant advance in sample preparation for RNA-based testing and analysis, and we are pleased to partner with leading reagent producer Quanta BioSciences to expand its availability,” said Paul Kinnon, CEO of ZyGEM.
Kinnon continued, “This agreement reinforces our strategy of partnering with innovative companies to bring the advantages of our accurate, fast and simple RNA and DNA extraction technologies to researchers around the globe.”
ZyGEM’s enzymatic technology uses a single tube process to provide complete extraction of RNA, including smaller RNA molecules such as non-coding RNA and micro-RNA that are excluded by other extraction methods.
It delivers higher molecular weight RNA and more representative transcriptome profiles than other methods and is well suited for complete gene expression and non-coding RNA analyses.
The technology has been shown to produce consistent, linear yields of nuclear RNA, thereby ensuring 100% reproducible results.
“As a leader in the design and manufacture of advanced reagents for quantitative biology, we are delighted to offer ZyGEM’s unique RNA extraction technology to our growing customer base,” said Will Geist, Vice President of Sales and Business Development at Quanta BioSciences.
“In our testing, ZyGEM’s technology rapidly produced high quality RNA, and we believe our customers will welcome the opportunity to obtain these benefits in their own work,” said David Schuster, Director of R&D at Quanta BioSciences.
Further terms of the agreement were not disclosed.
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Progressive Kidney Disease: New Compound Restores Kidney FunctionNews
A team led by researchers describe a new approach to prevent death in these essential kidney cells. Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function.READ MORE
New Drug Delivery System Targets Diseases at a Genetic LevelNews
A new drug delivery system that uses a synthetic-biological hybrid nanocapsule could provide a smart technology for targeted treatment of a variety of serious diseases at the genetic level.